The Neupro recall means that patients need to be switched from the patch to an oral dopamine agonist

The Neupro recall means that patients need to be switched from the patch to an oral dopamine agonist.

Neupro (rotigotine) was heralded as a big advance last year as the first patch for Parkinson's disease. It's a dopamine agonist similar to Mirapex (pramipexole) and Requip (ropinirole).

Now the patches are being recalled because of problems with crystals forming which could decrease drug delivery.